| Name | Title | Contact Details |
|---|
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company`s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, MD Anderson Cancer Center and ImmunoGen, Inc.
Stallergenes is a Norwell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ALX Oncology is a clinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Ibidi is a Verona, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lynxcom Partners LLC is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.